SCCS OPINION on benzyl salicylate (CAS No. 118-58-1, EC No. 204-262-9) _ SCCS/1656/23– Preliminary Opinion U. Bernauer, L. Bodin, Q. Chaudhry, P.J. Coenraads, M. Dusinska, J. Ezendam, E. Gaffet, C. L. Galli, E. Panteri, V. Rogiers, Ch. Rousselle, M. Stepnik, T. Vanhaecke, S. Wijnhoven, E. Benfentati, N. Cabaton, E. Corsini, A. Koutsodimou, H. Louro, W. Uter, N. von Goetz The SCCS adopted this document during its plenary meeting on 6-7 June 2023 2023 (68 Pages) Mise en ligne : 13 Juin 2023 https://health.ec.europa.eu/publications/benzyl-salicylate-cas-no-118-58-1-ec-no-204-262-9_en https://health.ec.europa.eu/system/files/2023-06/sccs_o_277.pdf Details Publication date : 13 June 2023 Author : Scientific Committee on Consumer Safety (SCCS) Description SCCS members: U. Bernauer, L. Bodin, Q. Chaudhry, P.J. Coenraads (Chairperson), M. Dusinska, J. Ezendam, E. Gaffet, C. L. Galli, E. Panteri, V. Rogiers, Ch. Rousselle (Rapporteur), M. Stepnik, T. Vanhaecke, S. Wijnhoven SCCS external experts: E. Benfentati, N. Cabaton (Rapporteur), E. Corsini, A. Koutsodimou, H. Louro, W. Uter, N. von Goetz Contact: SANTE-SCCS@ec.europa.eu On request from: European Commission SCCS Number: SCCS/1656/23 Adopted on: 6-7 June 2023 Conclusion of the opinion: (1) In light of the data provided and taking under consideration the concerns related to potential endocrine disrupting properties of Benzyl Salicylate, does the SCCS consider Benzyl Salicylate safe when used up to the maximum concentrations provided in the dossier submission by the Benzyl Salicylate Consortium? Based on the data provided and assessed and taking under consideration the concerns related to potential endocrine disrupting properties, the SCCS considers Benzyl Salicylate safe when used up to the maximum concentrations provided in Table 1 of this Opinion. (2) Alternatively, what is according to the SCCS the maximum concentration considered safe for use of Benzyl Salicylate in cosmetic products? / (3) Does the SCCS have any further scientific concerns with regard to the use of Benzyl Salicylate in cosmetic products? The available data on Benzyl Salicylate provide some indications for an endocrine mode of action, but there is no evidence that this results in potential endocrine effects. The SCCS mandates do not address environmental aspects. Therefore, this assessment did not cover the safety of Benzyl Salicylate for the environment. Keywords: SCCS, scientific opinion, benzyl salicylate, Regulation 1223/2009, CAS No. 118-58-1, EC No. 204-262-9 Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on benzyl salicylate (CAS No. 118-58-1, EC No. 204-262-9), preliminary version of 6-7 June 2023, SCCS/1656/23.